REGENXBIO Inc. (RGNX) Stock Forecast
RGNX analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.42 / 5 from 12 analysts
- Price target
- $23.58 average of analyst targets
- Upside to target
- +240.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.36
- 52-week range
- $5.65 – $15.98
RGNX analyst ratings
12 analystsNumber of analysts at each rating.
RGNX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RGNX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.30 | −$1.63 | −$0.89 | −$1.20 | −8.3% | 9 |
| Current fiscal year (2026) | −$3.49 | −$4.86 | −$1.03 | −$3.76 | +7.1% | 9 |
| Next fiscal year (2027) | −$2.98 | −$4.81 | $0.13 | −$3.49 | +14.8% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RGNX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $15.5M | $5.9M | $50.8M | −47.8% | 9 |
| Current fiscal year (2026) | $163.7M | $126.6M | $298.8M | −4.0% | 10 |
| Next fiscal year (2027) | $200.4M | $28.0M | $418.5M | +22.4% | 10 |
RGNX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RGNX revenue: reported and forecast
RGNX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.22 | −$1.27 | −$1.27 | −$1.30 | −$1.30 | +6.1% | 4 up · 2 down |
| Current fiscal year (2026) | −$2.82 | −$3.43 | −$3.52 | −$3.49 | −$3.49 | +23.7% | 4 up · 3 down |
| Next fiscal year (2027) | −$2.57 | −$2.31 | −$3.00 | −$2.98 | −$2.98 | +15.5% | 5 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RGNX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RGNX beat in 5 of 12.
What analysts expect from RGNX
12 analysts cover REGENXBIO; their consensus rating is buy (4.42 on a 1–5 scale, where 5 is a strong buy). The average price target is $23.58, 240.6% above the latest close of $6.92. Analysts expect earnings of −$3.49 per share for 2026, +7.1% from a year earlier. For 2027 the average estimate is −$2.98 per share on revenue of $200.4 million. REGENXBIO beat the EPS estimate in 5 of the last 12 quarters.
Related: RGNX income statement, RGNX key metrics, RGNX chart. See the RGNX stock overview for the latest quote and news.
RGNX forecast FAQ
What is REGENXBIO's price target?
The average analyst price target for REGENXBIO is $23.58, 240.6% above the latest close of $6.92.
Is REGENXBIO a buy, hold or sell?
Of 12 analysts covering REGENXBIO, 7 rate it a strong buy, 3 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is REGENXBIO's EPS forecast?
Analysts forecast −$3.49 per share for 2026 (range −$4.86 to −$1.03); for 2027 the estimate is −$2.98.
What is REGENXBIO's revenue forecast?
The average revenue estimate for 2026 is $163.7 million, growth of −4.0%; for 2027 it is $200.4 million.
When does REGENXBIO report earnings?
REGENXBIO is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-1.36.
Does REGENXBIO usually beat earnings estimates?
REGENXBIO reported EPS at or above the analyst estimate in 5 of the last 12 quarters.